Daratumumab

Daratumumab is a targeted therapy used to treat multiple myeloma, a type of blood cancer affecting plasma cells. It is a monoclonal antibody that specifically binds to a protein called CD38 found on myeloma cells. By attaching to CD38, daratumumab helps the immune system recognize and destroy these cancer cells. It can be used alone or with other treatments, and it has improved outcomes for many patients by attacking the cancer more precisely. Overall, daratumumab enhances the body's ability to fight multiple myeloma effectively.